<div id="subtitle">Pfizer CFO lowers forecast for 2012, post Lipitor's patent loss, but aims for better results</div><div><p>Drug maker Pfizer Inc., reporting its fourth-quarter results on Wednesday, also updated its financial forecast for 2012, when it faces a revenue cliff as generic competition arrives for its $11.4 billion-a-year cholesterol blockbuster Lipitor.</p><p>Lipitor is the world's top-selling drug.</p><p>Buying Wyeth in October brought Pfizer new products and drugs in development. Chief Financial Officer Frank D'Amelio said Pfizer is reducing its 2012 forecast due to other factors.</p><p>Pfizer now foresees annual revenue next year of $66 billion to 68.5 billion, compared with an earlier forecast of $70 billion. It predicts adjusted earnings per share of $2.30, down from $2.42.</p><p>QUESTION: Why are you lowering the 2012 forecast now?</p><p>RESPONSE: The 2012 targets reflect some things that have changed. (D'Amelio mentioned having to divest some of both Wyeth's and Pfizer's animal health products and give up rights to a drug Wyeth developed with another company.)</p><p>We went through a detailed process, we had the benefit of another year (of data) and we refined the numbers. ... Our job is to meet those targets and, to the extent we can do better than that, we will.</p><img src="http://admatch-syndication.mochila.com/images/ad.gif?aid=68396794&bid=informcom" /></div><div id="copyright"><div>

Copyright 2010  <a href="http://www.ap.org">AP News</a></div></div>